NASDAQ:ELAB Elevai Labs (ELAB) Stock Price, News & Analysis $4.37 -0.05 (-1.18%) Closing price 03:59 PM EasternExtended Trading$4.32 -0.04 (-0.98%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Elevai Labs Stock (NASDAQ:ELAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Elevai Labs alerts:Sign Up Key Stats Today's Range$4.27▼$4.6950-Day Range$3.92▼$21.7052-Week Range$3.88▼$1,064.00Volume21,557 shsAverage Volume135,743 shsMarket Capitalization$2.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewElevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Read More… Remove Ads Elevai Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreELAB MarketRank™: Elevai Labs scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Elevai Labs. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevai Labs has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Elevai Labs' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.74% of the float of Elevai Labs has been sold short.Short Interest Ratio / Days to CoverElevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevai Labs has recently increased by 14.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElevai Labs does not currently pay a dividend.Dividend GrowthElevai Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.74% of the float of Elevai Labs has been sold short.Short Interest Ratio / Days to CoverElevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevai Labs has recently increased by 14.95%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Elevai Labs this week, compared to 1 article on an average week.MarketBeat Follows6 people have added Elevai Labs to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elevai Labs insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.60% of the stock of Elevai Labs is held by insiders.Percentage Held by InstitutionsOnly 22.22% of the stock of Elevai Labs is held by institutions.Read more about Elevai Labs' insider trading history. Receive ELAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevai Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address ELAB Stock News HeadlinesElevai Labs (NASDAQ:ELAB) Stock Price Up 5.1% - What's Next?April 3 at 2:27 AM | americanbankingnews.comPMGC Holdings Inc. Announces Filing of Annual Report on Form 10-KMarch 28, 2025 | globenewswire.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health MarketMarch 27, 2025 | globenewswire.comUnivest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)March 24, 2025 | globenewswire.comPMGC Holdings Inc. Common Stock (ELAB)March 23, 2025 | nasdaq.comPMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq RulesMarch 21, 2025 | globenewswire.comPMGC Holdings Announces Share Repurchases from Existing ShareholdersMarch 21, 2025 | globenewswire.comSee More Headlines ELAB Stock Analysis - Frequently Asked Questions How have ELAB shares performed this year? Elevai Labs' stock was trading at $16.03 on January 1st, 2025. Since then, ELAB shares have decreased by 72.8% and is now trading at $4.3680. View the best growth stocks for 2025 here. When did Elevai Labs' stock split? Elevai Labs shares reverse split before market open on Monday, March 10th 2025. The 1-7 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Sunday, March 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. When did Elevai Labs IPO? Elevai Labs (ELAB) raised $6 million in an initial public offering (IPO) on Tuesday, November 21st 2023. The company issued 1,500,000 shares at $4.00 per share. Univest Securities served as the underwriter for the IPO. How do I buy shares of Elevai Labs? Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elevai Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII). Company Calendar Today4/04/2025Next Earnings (Estimated)4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMulti-Sector Conglomerates Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELAB Previous SymbolNASDAQ:ELAB CIK1840563 Webelevaiskincare.com Phone866-794-4940FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($433.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,300,000.00 Net Margins-223.41% Pretax Margin-223.37% Return on Equity-124.93% Return on Assets-85.10% Debt Debt-to-Equity Ratio0.06 Current Ratio3.86 Quick Ratio3.40 Sales & Book Value Annual Sales$2.45 million Price / Sales1.03 Cash FlowN/A Price / Cash FlowN/A Book Value$44.17 per share Price / Book0.10Miscellaneous Outstanding Shares578,000Free Float3,033,000Market Cap$2.53 million OptionableN/A Beta-2.95 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ELAB) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevai Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevai Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.